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Interventions 33 
Abstract 34 
Background: Context matters for the successful implementation of medical interventions, but its role 35 
remains surprisingly understudied. Against the backdrop of antimicrobial resistance, a global health 36 
priority, we investigated the introduction of a rapid diagnostic biomarker test (C-reactive protein, or 37 
CRP) to guide antibiotic prescriptions in outpatient settings and asked, “Which factors account for 38 
cross-country variations in the effectiveness of CRP biomarker test interventions?” 39 
Methods: We conducted a cross-case comparison of CRP point-of-care test trials across Yangon 40 
(Myanmar), Chiang Rai (Thailand), and Hanoi (Vietnam). Cross-sectional qualitative data were 41 
originally collected as part of each clinical trial to broaden their evidence base and help explain their 42 
respective results. We synthesised these data and developed a large qualitative data set comprising 130 43 
interview and focus group participants (healthcare workers and patients) and nearly one million words 44 
worth of transcripts and interview notes. Inductive thematic analysis was used to identify contextual 45 
factors and compare them across the three case studies. As clinical trial outcomes, we considered 46 
patients’ and healthcare workers’ adherence to the biomarker test results, and patient exclusion to 47 
gauge the potential “impact” of CRP point-of-care testing on the population level. 48 
Results: We identified three principal domains of contextual influences on intervention effectiveness. 49 
First, perceived risks from infectious diseases influenced the adherence of the clinical users (nurses, 50 
doctors). Second, the health system context related to all three intervention outcomes (via the health 51 
policy and antibiotic policy environment, and via health system structures and the ensuing utilisation 52 
patterns). Third, the demand-side context influenced the patient adherence to CRP point-of-care tests 53 
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and exclusion from the intervention through variations in local healthcare-seeking behaviours, popular 54 
conceptions of illness and medicine, and the resulting utilisation of the health system. 55 
Conclusions: Our study underscored the importance of contextual variation for the interpretation of 56 
clinical trial findings. Further research should investigate the range and magnitude of contextual effects 57 
on trial outcomes through meta-analyses of large sets of clinical trials. For this to be possible, clinical 58 
trials should collect qualitative and quantitative contextual information for instance on their disease, 59 
health system, and demand-side environment. 60 
Trial registration: ClinicalTrials.gov Identifiers NCT02758821 and NCT01918579. 61 
 62 
Keywords 63 
Intervention implementation, contextual factors, qualitative research, antibiotic prescription, 64 
Myanmar, Thailand, Vietnam 65 
 66 
Main Text 67 
Background 68 
“Context is key” [1] in medical interventions because it “interacts, influences, modifies and facilitates 69 
or constrains the intervention and the implementation effort” [2]. Contextual factors involve for 70 
instance patient characteristics, the political environment, organisational cultures, or the relationship 71 
between patients and healthcare staff [3-5], and we should expect them to influence the full spectrum 72 
of simple, pragmatic, and complex clinical trials, considering the extremely diverse health systems, 73 
socio-economic settings, and epidemiological environments across and within low-, middle-, and high-74 
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income countries [3, 5-11]. Researchers call for more research in this area because a better 75 
understanding of contextual factors can help to improve the implementation and operation of medical 76 
interventions [1, 2, 7]. 77 
Despite their importance, contextual factors in clinical interventions are surprisingly under-researched 78 
[12, 13]. Statistical analysis can help detect the presence of contextual influences on trial outcomes [7, 79 
14]; qualitative research can shed further light on the nature and underlying mechanisms of these 80 
influences [5, 10, 15, 16]. Among the few examples is Reynolds et al. [6], who compiled qualitative 81 
data from nine trials of malaria diagnostics and treatment across seven low- and middle-income 82 
countries (LMICs) to study real-life implementation processes (e.g. communication between sub-study 83 
teams) and their implications for trial data interpretation. 84 
The present study contributed to this narrow yet essential body of knowledge through a qualitative 85 
cross-case comparison of three diagnostic biomarker test trials in Southeast Asia. The objective of this 86 
paper was to illuminate how the trial context influenced the implementation and operation of medical 87 
interventions. Our definition of context followed Damschroder et al. [4] as “the set of circumstances 88 
or unique factors that surround a particular implementation effort.” 89 
Our study was situated against the backdrop of antimicrobial resistance (AMR). AMR is a global 90 
health priority that is feared to cause 10 million deaths annually by 2050 [17], the economic costs of 91 
which have been likened to the 2008 global financial crisis with a disproportionate impact on LMICs 92 
[18-21]. Yet, AMR is a global problem affecting also high-income countries, as can be seen in a recent 93 
case of multi-drug-resistant Neisseria gonorrhoeae originating in Southeast Asia that had been 94 
detected in the UK [22]. Among the many factors that contribute to AMR is the over- and mis-use of 95 
antibiotics especially for non-bacterial infections [19, 20, 23]. Across low-, middle-, and high-income 96 
countries, such over-use has been attributed partially to antibiotic over-prescription [23-26]. Various 97 
interventions are therefore being explored to change prescription patterns [25, 27], among which 98 
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diagnostic technologies to improve the behaviour of antibiotic prescribers have received particular 99 
attention [28-31]. 100 
This study focused on one such diagnostic technology, namely a point-of-care finger-prick blood test 101 
for C-reactive protein (CRP). CRP point-of-care tests (POCTs) had been designed to help healthcare 102 
staff at the primary-care level to distinguish bacterial from non-bacterial infections [32, 33]. They had 103 
been evaluated in high-income countries [34-36], but LMICs are particularly interesting settings for 104 
CRP POCTs for two main reasons: (1) the widespread over-use of antibiotics alongside the higher risk 105 
of under-treating potentially severe bacterial infections, and (2) the frequent absence of state-of-the-106 
art laboratory facilities at the primary-care level [37, 38]. 107 
We situated our study within large-scale clinical trials of CRP POCTs in Yangon (Myanmar), Chiang 108 
Rai (Thailand), and Hanoi (Vietnam). The purpose of this paper was not to ascertain whether these 109 
CRP POCTs met their objectives (which we report elsewhere [39]), but rather to understand how a 110 
standardised intervention—implemented with similar trial design and outcome measurement in 20 111 
primary-care sites of three Southeast Asian countries—could yield heterogeneous outcomes. For 112 
example, while overall prescriptions of antibiotics decreased in the clinical trials, there were variable 113 
and often high degrees of prescribing in patients with a negative test result (i.e. no antibiotic 114 
recommended). Healthcare workers’ adherence to a negative test result was 78% on average in 115 
Thailand, 81% in Myanmar, and 65% in Vietnam. In the case of Vietnam, these rates varied from 29% 116 
to 96% across the participating sites (based on reported immediate prescriptions [39]). 117 
We collected a wealth of qualitative data alongside the clinical trials to contextualise such 118 
heterogeneous study outcomes. We drew in this paper exclusively on this qualitative data to answer 119 
the question, “Which factors account for cross-country variations in the effectiveness of CRP 120 
biomarker test interventions?” Covering nearly one million words worth of transcripts and interview 121 
notes from 130 respondents, the extent and granularity of our qualitative data allowed us to carry out 122 
a cross-case comparison using thematic analysis [40] and contribute an original perspective to the 123 
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understanding of contextual factors in clinical interventions. We thereby also contributed to the 124 
qualitative research of CRP POCT, which had thus far only involved single-case studies in high-125 
income settings [41, 42]. 126 
 127 
Methods 128 
Study Design 129 
The CRP POCT trials were situated in Southeast Asia, which is deemed a global AMR epicentre due 130 
to its widespread unregulated antibiotic use in humans and animals [43-45]. The qualitative data were 131 
collected in a cross-sectional design as part of the clinical trials, involving participating healthcare 132 
workers (HCWs) and patients (see Table 1 for an overview of the clinical trials). The initial intention 133 
of this qualitative data collection was to broaden the evidence base and help explain the results of each 134 
clinical trial individually [46]. More specifically, the objective of the qualitative data collection in 135 
Chiang Rai and Yangon was to contextualise the CRP POCT “within an existing system of practices 136 
at the patient-health system interface” [47]; the Hanoi data was collected to “assess the acceptance of 137 
CRP [point-of-care] testing to reduce inappropriate antimicrobial use for self-limiting [acute 138 
respiratory infections] among patients [incl. guardians of children patients] and HCWs in Vietnam” 139 
[48]. Although the initial intention of the qualitative data collection was not to carry out a cross-case 140 
comparison, the qualitative data sets contained extensive and compatible context-related information 141 
(e.g. patients’ conceptions of illness, HCW perceptions of patient expectations) that enabled a 142 
secondary analysis across the three trial case studies. We therefore synthesised the qualitative data 143 
from the three trials and compiled a large qualitative data set, using inductive thematic analysis (i.e. 144 
without predefined themes) to identify factors that accounted for cross-case variation in the 145 
effectiveness of the CRP POCT trials [49]. 146 
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Table 1. Clinical Trial Characteristics 147 
 Case Study 
 Chiang Rai 
(Thailand) 
Yangon  
(Myanmar) 
Hanoi 
(Vietnam) 
Study 
Population 
Febrile patients Febrile patients 
Patients with acute 
respiratory infections 
Trial Sample 
1,182 participants (600 
adults, 582 children) 
1,228 participants (609 
adults, 619 children) 
2,036 participants (1,008 
adults, 1,028 children) 
CRP POCT 
Usersa 
Nurses and Public Health 
Technical Officersb 
Medical doctors Medical doctors 
Location 
Peri-urban  
Chiang Rai district 
Hlaing Tha Yar and Shwe 
Pyi Thar sub-urbs 
Rural & urban  
Hanoi 
Study Sites 
6 public primary  
healthcare centres 
3 NGO clinics &  
1 public hospital 
9 public primary healthcare 
centres (urban) & 1 public 
district hospital (rural) 
Source: Authors. 148 
Notes: CRP POCT is “C-reactive protein point-of-care test;” HCW is “healthcare worker;” NGO is “non-governmental organisation.” 149 
a. “Users” refers here to the healthcare workers who interpreted the test results. The trials involved dedicated study staff to operate the 150 
CRP POCT, which would not necessarily be the case in routine settings. 151 
b. For simplicity, we will only refer to “nurses” when considering healthcare workers in Chiang Rai. 152 
 153 
The target populations for the clinical trial in Hanoi were patients with non-severe acute respiratory 154 
infections, which represented a group of particularly high (and potentially ineffectual) antibiotic use 155 
in Vietnam [50]. The trials in Chiang Rai and Yangon focused on febrile patients, considering the 156 
regional endemicity of malaria alongside the limited range of diagnostic aides to guide treatment for 157 
undifferentiated fevers [32]. These target groups are comparable in their clinical presentation and 158 
represent the commonest causes of attendance in primary care. The target samples of the clinical trials 159 
involved 1,200 patients each in Chiang Rai and Yangon and 2,000 in Hanoi, each comprising 50% 160 
adults and 50% children (4,446 trial participants were recruited in total). As part of the consent process, 161 
all trial patients were provided with brief information in the local language about the role of antibiotics 162 
and the risk of antibiotic resistance. 163 
The clinical trials assessed the effectiveness of a CRP POCT on reducing antibiotic prescriptions at 164 
urban, peri-urban, and rural primary-care-level healthcare facilities. As a diagnostic tool, CRP 165 
indicates whether a patient is likely to have a bacterial infection, and the CRP POCT was intended to 166 
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discourage HCWs from prescribing an antibiotic below a certain threshold that indicated the absence 167 
of bacterial infections (10 and 20mg/L in children and adults in Hanoi, respectively; and two 168 
intervention arms using 20 and 40 mg/L thresholds in Chiang Rai and Yangon). The CRP POCT was 169 
administered as a finger-prick blood test, and a reader device (NycoCard II® reader) reported CRP 170 
levels within five minutes (for a more detailed description of the process, see [47]). The participating 171 
primary healthcare facilities in Chiang Rai comprised public health centres staffed with nurse 172 
practitioners and public health technical officers. In Yangon, the outpatient department of a 173 
government hospital and clinics run by a local non-governmental organisation were staffed with 174 
medical doctors, and so were the public health centres and the public district hospital in Hanoi. 175 
Healthcare staff in all three sites received the CRP POCT results from dedicated study staff, namely 176 
study nurses in Chiang Rai and study doctors in Yangon and Hanoi. The HCWs would then use the 177 
CRP POCT results to complement their clinical judgement. 178 
Qualitative Data Collection 179 
The qualitative sampling strategies and the ensuing samples are summarised in Table 2. In Chiang Rai, 180 
all participating HCWs were recruited, whereas the Yangon and Hanoi studies sampled at least one 181 
HCW from each participating site depending on their experience with the CRP POCT and their 182 
availability. Patient sampling in Hanoi involved a random sample of the patients in the treatment 183 
groups (incl. guardians of children patients), recruited successively until data saturation was reached 184 
(defined as no new themes arising from two consecutive focus group discussions / semi-structured 185 
interviews, which can already occur after 10-12 interviews [51, 52]). In Chiang Rai and Yangon, 186 
purposive maximum variation samples were obtained specifically to capture differences across the 187 
target population. The variables guiding the patient selection were the allocation to the trials’ 188 
randomisation group, antibiotic prescription, sex, age, and education level. To understand the 189 
intervention context more comprehensively, the Chiang Rai and Yangon samples also included febrile 190 
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patients who did not participate in the clinical trial (sampled through patient logs of the healthcare 191 
facilities). The resulting qualitative data set involved 130 participants and comprised semi-structured 192 
interviews (SSIs, lasting 30 to 90 minutes) and focus group discussions (FGDs, lasting one to two 193 
hours). 194 
 195 
Table 2. Qualitative Sample Characteristics 196 
 Case Study 
 Chiang Rai 
(Thailand) 
Yangon  
(Myanmar) 
Hanoi 
(Vietnam) 
Timing of Data 
Collection 
August 2016,  
May 2017 
December 2016 –  
January 2017 
June – December 2015 
 Healthcare Worker Sample 
Sample Size 
21 HCWs 
(16 female / 5 male) 
12 HCWs 
(6 female / 6 male) 
12 HCWs 
(10 female / 2 male) 
Sampling 
Strategy 
Census 
(all participating HCWs) 
Purposive sample 
(at least 1 from each site)a 
Purposive sample 
(at least 1 from each site)b 
Semi-Structured 
Interviews 
21 SSIs 12 SSIs 2 SSIs 
Focus Group 
Discussions 
None None 1 FGD (10 participants) 
 Patient Sample 
Sample Size 
37 patientsc 
(control and treatment; 
24 female / 13 male, 
average age: 42 years) 
21 patientsc 
(control and treatment; 
13 female / 8 male, 
average age: 37 years) 
27 patientsc 
(treatment group only; 
23 female / 4 male, 
average age: 49 years) 
Sampling 
Strategy 
Purposive sample 
(maximum variation)d 
Purposive sample 
(maximum variation)d 
Random sample with 
information saturatione 
Semi-Structured 
Interviews 
25 SSIs (incl. 2 interviews 
with 2 participants) 
11 SSIs (incl. 1 interview 
with 2 participants) 
9 SSIs 
Focus Group 
Discussions 
3 FGDs (3 male, 4 female, 
3 female guardians) 
2 FGDs (4 male, 5 female; 
mixed adult/guardian) 
3 FGDs (5/6/7 participants; 
male/female/guardian) 
Source: Authors. 197 
Notes: HCW is “healthcare worker.” “Guardian” defined as a interview participant who signed consent for a child participating in the 198 
clinical trial, or non-trial respondent who was responsible for care of a child. However, guardians reported on their own health behaviour 199 
as well as their children’s. 200 
a. Respondents within sites selected on basis of availability. 201 
b. Respondents within sites comprising main study doctors who enrolled more than 80% of centre’s sample size. At least one such doctor 202 
per site would participate in the focus group discussion. In two sites, there were two such doctors; one would participate in the focus 203 
group discussion and one each would participate in a semi-structured interview. 204 
c. Including patients and guardians of child patients. 205 
d Maximum variation across the following variables: patients’ study groups (pre-intervention/control/treatment group), antibiotic 206 
prescription (yes/no), sex (male/female), age (guardian of a child below 18 years/18-49/50+), education (below/above primary 207 
education). 208 
e Saturation criterion: no new themes arose from two consecutive focus group discussions / semi-structured interviews. 209 
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 210 
Box 1. Qualitative Data Collection Topics and Example Questions 211 
Patients in Chiang Rai and Yangon Patients in Hanoi 
Medicine use and treatment-seeking behaviour (“You recently 
visited the health centre because of a fever. What was the process of getting 
treatment? Please be as specific as possible, step by step.”) 
Decision-making about medicines (“When would you use 
medicines for an illness? When not?”) 
Demand-side preferences, local notions and myths about 
medicine (“What is the best treatment for fever?”) 
Health provider landscape and preferences from patient 
perspective (“Can you tell me which health providers are available to you, 
and which of them you would visit for treatment?”) 
Experiences in public healthcare (“For your visit at the health 
centre, can you please tell me: How did you feel if you did not receive the 
medication you expected?”) 
CRP POCT experiences (“Do you feel that you were treated differently 
than usual because of the test?”) 
Acute respiratory infections (ARIs) 
and treatment-seeking behaviour 
(“What is your understanding about the causes of 
ARI and its natural history?”, “Why did you choose 
to visit the clinic on this occasion?”) 
Perception of CRP testing (“Does the test 
need to be improved? If yes, how?” 
Impact on antimicrobial use (“What do 
you expect from seeing the doctor with ARI?”, “Did 
you seek for subsequent antimicrobials if your 
doctor did not give you antimicrobial?”) 
Impact on consultation (“What other 
information would you need to help you fully trust 
the test and trust the doctor's opinion that you do 
not need antimicrobials?”) 
Recommendations (“In your opinion, should 
a CRP test be done as a part of routine diagnosis 
for ARI patients in primary care settings?”) 
Healthcare Workers in Chiang Rai and Yangon Healthcare Workers in Hanoi 
Workload, freedom and constraint in work (“What are your 
roles and responsibilities in your work”) 
Scope of outpatient work (“How many outpatients do you deal with 
on a normal day”) 
The system context of CRP POCT (“Are any tests being carried 
out (e.g. by yourself) to diagnose [common outpatient complaints]?”) 
Antibiotics marketing (“Do drug company representatives promote the 
use of certain medicines in your health centre?”) 
Extent of patient demand, dynamics in patient–HCW 
interaction (“Do patients demand certain drugs or treatments?”) 
Antibiotics prescription practice (“For what conditions do you 
prescribe antibiotics?”) 
Risk reduction through antibiotics (“Can antibiotics be a way to 
protect you from patient demands, ineffective treatment, or problems in 
diagnosing an illness?”) 
(Measures to limit) over-prescription (“If you had to reduce 
antibiotics prescriptions, what would you consider the most effective way?”) 
Perception of CRP testing (“What do you 
like / dislike about the test?”) 
Impact on antimicrobial prescription 
(“How did the test support your treatment 
decision?”, “What do you think your patients are 
expecting from seeing a doctor? (Drugs / 
Antimicrobials / Advice / Reassurance / Diagnosis / 
Others)”) 
Impact on consultation (“Did you use the 
CRP result to discuss with patients about your 
treatment decision?”) 
Recommendations (“In your opinion, should 
a CRP test be introduced in routine practice of your 
setting? Why / Why not?”) 
Source: Haenssgen et al. [47], Do [48]. 212 
Note: Healthcare worker interviews in Chiang Rai and Yangon initially included vignettes to explore understanding of best practices, 213 
which were dropped due to time constraints. 214 
 215 
The topics of the data collection instruments were based on the literature around frontline healthcare 216 
workers, treatment seeking and antibiotic use in LMICs, and rapid diagnostic testing for malaria [53-217 
55]. SSI and FGD guides covered similar topics, which are summarised in Box 1 (the complete 218 
interview guides are presented in [47, 48]). The FGDs focussed on triangulating insights from the SSIs 219 
and therefore did not explore the topics in the same level of depth. All interviews and discussions were 220 
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conducted in the local languages (Burmese, [Northern] Thai, Vietnamese) and yielded approximately 221 
98 hours of audio-recorded material. The audio records were transcribed and translated by the study 222 
team members who conducted the interviews. The transcripts were complemented with written notes 223 
describing for instance the interview setting and non-verbal communication. The resulting 977,000 224 
words of written material formed the basis of our qualitative data analysis. 225 
Qualitative Data Analysis 226 
Considering the scarcity of knowledge on contextual factors and their “subjectivity” [3], we chose an 227 
inductive thematic analysis approach for this cross-case comparison. This means that we developed 228 
themes from the narratives of patients and healthcare workers who were involved in the trials (although 229 
different from a “grounded theory approach,” this is sometimes referred to as “grounding” themes in 230 
the qualitative data [56]; the inductive approach is opposed to a deductive approach that would explore 231 
themes derived from theory or the literature [49]). 232 
The trial outcomes that we considered were (1) patient adherence and (2) healthcare worker (or 233 
“clinical user”) adherence to the biomarker test results, and (3) patient exclusion to gauge the potential 234 
“impact” of CRP point-of-care testing on the population level (e.g. even if user and patient adherence 235 
were high, the trial impact may be diminished if the CRP POCT only reaches a small fraction of the 236 
population). Following the process description for qualitative cross-case comparisons by Bazeley [40], 237 
the analysis took place in three stages: First, description of each individual case study; second, 238 
identification of similarities and differences of each case in relation to the trial outcomes through 239 
pairwise comparisons; and, third, interpretation of key variables influencing the trial outcomes in the 240 
three case studies. 241 
In Stage 1, all textual material was read and coded using Nvivo 11 [57]. Codes were assigned in relation 242 
to any of the three outcomes, starting with the SSI transcripts as our primary data source, which we 243 
triangulated with FGD transcripts (interview notes provided an overview and contextualising 244 
AUTHOR ACCEPTED MANUSCRIPT  Page 12 
information). The triangulation through FGD transcripts involved checks of completeness and 245 
representation of statements from the SSIs, whereby we analysed participants’ contributions 246 
individually in the context of the dynamic evolution of the discussion (see [58]; this corresponds to 247 
participant-based group analysis, as opposed to whole-group analysis [59]). In order to ensure 248 
consistency of the coding frame across the three case studies, this stage involved two coding rounds 249 
of all textual material and was conducted in a single-coder approach by the lead social scientist (MJH; 250 
ambiguities in meaning in the translated transcripts were clarified during this stage through the local 251 
study team members NC, NTTD, YKZ). 252 
In Stage 2, each individual case study was compared pairwise against the remaining two cases, the 253 
similarities and differences of which were tabulated in a cross-case comparative matrix. After a first 254 
round of comparative coding by the lead social scientist, the matrix was validated and amended by the 255 
local study team members who were involved in the qualitative data collection (NC, NTTD, YKZ), 256 
and by the team members who coordinated the clinical trials across the three countries (TA, NTTD). 257 
This validation process involved the critical interrogation and challenge of the identified themes (e.g. 258 
in light of the original-language transcripts) and the consideration of alternative or omitted themes. 259 
This joint deliberation entailed a further round of analysis of all textual material relating to challenged 260 
or omitted themes. 261 
In Stage 3, the study team derived jointly the key themes of the analysis, namely contextual domains, 262 
outcomes, and the pathways linking them. In light of space constraints, we focussed our presentation 263 
of the results on the key themes and the cross-case comparative matrix; an in-depth description of each 264 
individual case is provided in Additional file 1. We further refrained in this paper from linking 265 
quantitative outcome measures to the qualitative themes, considering the breadth of the latter (in 266 
statistical terms, we would have fewer observations than variables to specify the exact relationship). 267 
 268 
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Results 269 
Fig. 1 summarised the key themes of our qualitative analysis and illustrated the pathways (depicted in 270 
green) through which the CRP POCT trial outcomes (dark blue) were affected by three inter-related 271 
domains of contextual factors (light blue). The first domain was perceived infectious disease risks, 272 
defined as treatment risks stemming from the disease environment as healthcare workers evaluate them 273 
in their routine practice (rather than “objective” measures of disease burden in the local area). Second, 274 
the health system context comprised health policies and guidelines that governed the work of 275 
healthcare workers, and the structure of the health system. Third, the demand-side context related to 276 
local healthcare-seeking behaviours and popular conceptions of illness and medicine, and the resulting 277 
utilisation of the health system among patients. We exemplified the concrete manifestations of these 278 
elements across our three case studies in Table 3 and described the main elements in detail in the 279 
remainder of this section, structured according to the three contextual domains. 280 
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281 
Fig. 1. Contextual Factors Influencing CRP POCT 282 
Source: Authors, derived from qualitative analysis. 283 
Note: “Health systems” comprise here all formal and informal actors involved in promoting, maintaining, or restoring health according 284 
to WHO [60], which can include e.g. medicine-selling grocery stores alongside public and private hospitals. 285 
 286 
 287 
Clinical User 
Adherence
(doctors’ and 
nurses’ adherence 
to CRP POCT 
results)
Perceived 
Infectious 
Disease Risks
(how perceived 
treatment risks 
influence healthcare 
workers’ routine 
practice)
Health System 
Context
(how health policies 
and guidelines 
influence the work 
of healthcare 
workers; and which 
[public / private / 
informal] treatment 
options the health 
system offers for 
patients)
Demand-Side 
Context
(how people make 
sense of illness and 
medicine, and how 
they navigate the 
local health system)
Healthcare 
Workers’ 
Fear of Life-
Threatening 
Infections
Protection 
From 
Repercus-
sions of Non-
Prescription
Attributes 
and 
Behaviour of 
Clinical CRP 
POCT Users
Health 
System 
Structure
Patient –
Healthcare 
Worker 
Interactions
Popular 
Conceptions 
of Illness and 
Medicine
Patient 
Adherence 
(degree to which 
patients follow 
CRP POCT-based 
treatment 
recommendations)
Patient 
Exclusion 
(from CRP POCT 
intervention on 
primary care level)
Drug Supply 
Conditions
Alternatives
to Antibiotic 
Prescription
Health Policy 
and 
Antibiotic 
Policy 
Environment
Healthcare 
Utilisation
Trial 
Outcomes
Contextual 
Domains
Pathways
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Table 3. Summary of Contextual Impact on Outcomes of Clinical Trials 288 
 Case Study 
 Chiang Rai  
(Thailand) 
Yangon  
(Myanmar) 
Hanoi 
(Vietnam) 
Perceived 
Infectious 
Disease 
Risks 
Clinical User Adherence (UA) to CRP POCT Results 
Nurses perceive low risk of life-
threatening infectious diseases 
and refer risky/uncertain cases to 
hospital (higher UA) 
Doctors bear and own higher treatment risk 
(lower UA) 
Health 
Policy 
Context 
Clinical User Adherence (UA) to CRP POCT Results 
Healthcare workers acknowledge 
antibiotic stewardship policies 
(higher UA) 
Antibiotic policies are absent or unenforced (lower UA) 
Antibiotic supply is monitored 
strictly (higher UA) 
Antibiotic supply is unrestricted (lower UA) 
Nurses use medical and herbal 
alternatives for antibiotic 
prescription (higher UA) 
Doctors lack non-antibiotic alternatives (lower UA) 
Nurses have limited POCT / blood 
test experience (higher UA)  
Doctors have extensive diagnostic testing experience  
(lower UA) 
Patient Exclusion (PE) From CRP POCT Intervention on Primary Care Levela 
Seasonal (e.g. harvest) and 
spatial constraints (e.g. 
mountainous areas) (higher PE) 
Healthcare access 
constraints for poor 
patients (higher PE) 
Rural healthcare access 
constraints (higher PE) 
Patient Adherence (PA) to CRP POCT-Based Treatment 
Patients compensate tedious 
health facility visits with 
medicine requests  
(lower PA) 
Patients commonly use over-the-counter antibiotics (lower PA) 
 
Health insurance increases 
relative price of over-the-counter 
medicine (increased PA) 
Demand-
Side 
Context 
Patient Exclusion (PE) From CRP POCT Intervention on Primary Care Level 
Patients self-treat with antibiotics without heath facility visit (higher PE) 
Patients’ expectations for antibiotics do not correspond to trial 
focus on fever (higher PE) 
Trial focus on acute 
respiratory infections 
corresponds to patient 
expectations for antibiotics 
(lower PE) 
Patients may not know what antibiotics are or whether they have 
ever taken them (higher PE) 
Patient Adherence (PA) to CRP POCT-Based Treatment 
Patients’ understanding of antibiotics is very diverse, rendering 
educational messages less effectual (lower PA) 
Patients have common 
understanding of antibiotics 
and bacterial infection  
 (higher PA)  Patients over-estimate CRP POCT capabilities (higher PA) 
Source: Authors, derived from qualitative analysis. 289 
Notes: Higher patient exclusion (PE) and lower user/patient adherence (UA, PA) correspond to a negative impact of contextual factors 290 
on trial outcomes and are indicated in red; lower exclusion and higher adherence are indicated in green. References to “patients” do not 291 
imply uniform responses of the target group. 292 
a. Items in this category relate to the type of patient being excluded from the intervention. 293 
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Perceived Infectious Disease Risks 294 
The first contextual influence involved HCWs’ perceptions and fears of potentially life-threatening 295 
infections and the extent to which they owned and managed the associated treatment risks (e.g. through 296 
referral). A doctor in Hanoi suggested for instance that antibiotic prescription decisions related partly 297 
to individual risks that the clinical users (i.e. HCWs) of CRP POCT faced in their treatment: 298 
 299 
“If we prescribe antibiotics, we would not be blamed for any problem the patients might have. 300 
If we don’t prescribe antibiotics, the patients might get worse. In this case, we would not be 301 
able to explain to their relatives. And they would not accept our explanation.” (Doctor, Hanoi, 302 
FGD) 303 
 304 
Perceptions of risks may thereby correspond only partially to the actual epidemiological environment. 305 
For example, a survey in Vietnam by Minh [61] detected very low rates of pneumonia of 1.2% among 306 
563 outpatients with acute respiratory infections visiting a tertiary referral hospital for paediatrics [61]. 307 
Yet, doctors in Hanoi repeatedly expressed the need to protect themselves from potentially under-308 
treating such infectious diseases as well as “co-infections of both viral and bacterial infections” by 309 
over-prescribing (Doctor, Hanoi, SSI). 310 
We observed similar tendencies in the Yangon clinics, which catered especially to TB and HIV patients 311 
and which were situated among squatter populations with poor hygiene and environmental conditions 312 
[62, 63]. The participating doctors would thus describe common risks of co-infection and that, “If [the 313 
CRP test result is] low and [the patient’s] condition is bad, and there is bacterial infection, what we 314 
fear most in the bacterial infection is the pneumonia. So for that we would give [antibiotics] even if the 315 
CRP is low” (Doctor, Yangon, SSI). Considering the possibility of co-infection, antibiotics were also 316 
often prescribed as a prophylactic treatment especially for patients whom the doctors considered to be 317 
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high-risk groups (e.g. children, malnourished patients, or those from lower socio-economic 318 
backgrounds: “some [patients] are very weak, so then I give antibiotics, but for patients with asthma 319 
or heart failure by birth, or children, I give antibiotics even if they are not weak, because they are 320 
more prone to infection;” Doctor, Yangon, SSI). 321 
In contrast to the experiences from Yangon and Hanoi, respondents in Chiang Rai would only 322 
occasionally express a need for prophylactic prescriptions, considering the different patient profiles 323 
resulting for example from higher average wealth and access to improved sanitation facilities (e.g. 324 
access to improved sanitation in Thailand was 93% in 2015, compared to 78% in Vietnam and 80% in 325 
Myanmar [64]; see Additional file 1 for details). However, when for example pneumonia was 326 
suspected, one nurse explained that, “mostly we’d have to refer and a medical doctor will take care of 327 
it because that’s something quite serious” (Nurse, Chiang Rai, SSI). Referral mechanisms therefore 328 
mitigated the remaining risks for the nurses when patients had low CRP but suspected pneumonia, 329 
which underlined the role of the health policy environment as a further determinant of the risks that 330 
HCWs perceived when not prescribing an antibiotic. 331 
In summary, perceived infectious disease risks undermined user adherence with CRP POCT insofar 332 
as it created a fragile balance between clinical judgment and the fear of missing a bacterial infection. 333 
Perceived infectious disease risks when refusing patients antibiotics on the basis of a negative CRP 334 
POCT could include social pressure as well as adverse patient outcomes. Such situations appeared 335 
more pronounced in Yangon and Hanoi: doctors more commonly articulated fears of undertreating 336 
potentially life-threatening infections and they owned treatment risks to a greater extent than the nurses 337 
in Chiang Rai. 338 
 339 
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Health System Context 340 
Policy Environment 341 
The health policy environment related to three important themes in our data: (1) the supply 342 
environment of antibiotics, (2) the range of available alternatives to antibiotic treatment, and (3) the 343 
characteristics of HCWs as users of the CRP POCT. 344 
First, the supply environment contributed to the liberty with which HCWs could prescribe antibiotics. 345 
With the 2007 Antibiotic Smart Use campaign and the 2017-2021 National Strategic Plan on 346 
Antimicrobial Resistance, Chiang Rai experienced a higher-level drive towards better stewardship 347 
alongside local initiatives like stricter monitoring of primary-care-level antibiotic prescriptions [65-348 
68]. A health centre director described the situation as follows: “the policies from the ministry […] 349 
would focus [increasingly] on antibiotics. […] It’s the kind of work of which if we don’t reach the goal, 350 
our expenses or income and things like that from that particular performance will decrease” (Nurse, 351 
Chiang Rai, SSI). In this strict supply environment, the CRP POCT emerged as a complementary tool 352 
to help meet the policy requirement of lower antibiotic prescription. 353 
In contrast, health policy in Myanmar and Vietnam had hitherto focused on expanding the availability 354 
of antibiotics, while existing AMR-related policies in Vietnam had remained largely unenforced (e.g. 355 
the 2005 Drug Law; [45, 50, 69-71]). One manifestation of the comparatively lax regulation was that 356 
HCWs experienced no supply restrictions when prescribing antibiotics (notwithstanding the limited 357 
spectrum of available antibiotics). A doctor in an NGO clinic in Yangon described for instance that 358 
antibiotics were well-stocked compared to other medicines: “We may run out of stock for other 359 
medicines but not the antibiotics. Because I think that according to seasonal needs during these months 360 
it’s quite high and we have a lot more consultation” (HCW, Yangon, SSI). Such availability of 361 
antibiotics was even more pronounced in Hanoi, where some respondents experienced a supply glut 362 
of antibiotics to an extent that would render the CRP POCT almost superfluous: 363 
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 364 
“100% of patients have been provided with antibiotics as here are a lot of antimicrobials in 365 
stock that need to be dispensed. Depending on CRP results, I tell my patients to use the 366 
antimicrobial immediately or keep for another illness episode.” (Doctor, Hanoi, FGD) 367 
 368 
In other words, adherence appeared to drop in conditions of lax regulation and abundant supply. 369 
Second, the presence and promotion of alternatives to antibiotic prescription influenced adherence as 370 
well. When asked whether she would prescribe antibiotics to insisting patients, a nurse in Chiang Rai 371 
for example explained, “Sometimes I would change to herbal medicines instead because here we have 372 
herbal medicines. Instead of antibiotic, I can give them Fah Talai Jone [ฟ้าทะลายโจร] to avoid their 373 
antibiotic use, I can use that technique” (Nurse, Chiang Rai, SSI). In Chiang Rai, such alternatives 374 
were promoted by antibiotic stewardship initiatives and complemented both the strict regulatory 375 
environment and the CRP POCT intervention (another common technique was to defer prescription 376 
[47]). The opposite situation materialised in Yangon. The participating NGO clinics (specialising in 377 
TB and sexually transmitted infections) would stock only a narrow range of general medicine like 378 
cough suppressants. This meant that doctors had to rely on antibiotics for want of more appropriate 379 
choices: “If we can get other suppressants, other supported treatment, then we wouldn’t use antibiotics 380 
when we hear crepitations” (Doctor, Yangon, SSI). The limited range of non-antibiotic medicine for 381 
general patients therefore undermined doctors’ ability to adhere to a negative CRP POCT result. 382 
Third, the policy environment also shaped the characteristics of HCWs, for example their awareness 383 
of antibiotic resistance. It was common in all three contexts for HCWs to ignore antibiotic resistance 384 
as a local problem relevant to their routine practice: 385 
 386 
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“I don’t think [antibiotic over-prescription] is a problem in health centres. Because you need 387 
to prescribe it anyway, it’s a principle. If you don’t, the patients cannot get better.” (Nurse, 388 
Chiang Rai, SSI) 389 
 390 
“It is not the problem of my clinic. We do not have the pressure of prescribing antibiotics.” 391 
(Doctor, Hanoi, FGD) 392 
 393 
“Doctors mainly have limitations [i.e. guidelines when using antibiotics], but I think that the 394 
drug stores are out of control. Doctors have their ethics so…” (Doctor, Yangon, SSI) 395 
 396 
However, the comparatively active policy environment in Chiang Rai meant that the nurses had been 397 
widely exposed to the problem through national policies (“they want us to focus on [antibiotic] ‘Smart 398 
Use’ [a campaign to raise awareness and reduce antibiotic use];” Nurse, Chiang Rai, SSI), operational 399 
guidelines, and the media (“a lot of us [nurses] began to use social [media] now so that increases the 400 
knowledge for us;” Nurse, Chiang Rai, SSI), while also recognising a greater degree of public 401 
awareness (“the patients learn from the media [i.e. TV], as well;” Nurse, Chiang Rai, SSI). The 402 
implementation of the CRP POCT in this environment resonated with the existing degree of antibiotic 403 
stewardship. We could not discern such a link in the weaker AMR policy environments of Yangon and 404 
Hanoi. A doctor in Yangon indicated for instance that, “Oh, we don’t have it here [i.e. initiatives to 405 
reduce antibiotic use]” (Doctor, Yangon, SSI). 406 
A final example of health policy context was its influence on primary-care-level antibiotic prescribers’ 407 
prior experience with point-of-care and laboratory tests. Considering that only few diagnostic 408 
technologies were available at the primary care level in Chiang Rai (e.g. finger-prick blood glucose 409 
testing [72]), the introduction of a novel point-of-care test was often received favourably by the 410 
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participating nurses. For example, a nurse described that, “I check on the patients and they would feel, 411 
like, like, ‘Our hospital [i.e. health centre] is modern,’ you know? […] It’s like it’s upgraded our class 412 
to something higher, and we seem better” (Nurse, Chiang Rai, SSI). The technological enthusiasm was 413 
not echoed in Yangon and Hanoi, where the doctors were familiar with a range of diagnostic testing 414 
technologies and their hospital and specialised clinic environments offered a variety of testing facilities 415 
and routine blood tests (“frankly speaking, we can get X-ray and do something more informative;” 416 
Doctor, Yangon, SSI). Nuanced and conservative attitudes towards the intervention based on broader 417 
experiences with diagnostic technologies therefore suggested a lower degree of reliance on and 418 
adherence to the CRP POCT in Yangon and Hanoi. 419 
In summary, our interviews indicated a strong link between the health policy environment and HCWs’ 420 
adherence to the CRP POCT intervention. The policy environment shaped the antibiotic supply 421 
environment and the monitoring thereof, the availability of alternatives to antibiotic treatment, and the 422 
characteristics of the primary-care-level users of CRP POCT. In Chiang Rai, this created 423 
complementary conditions for the intervention and reinforced nurses’ trust in and adherence to CRP 424 
POCT. The opposite was the case in Hanoi and Yangon, where unrestricted antibiotic supply together 425 
with a lax regulatory environment, limited concerns about antibiotic resistance in HCWs’ routine 426 
practice, and experience with a wide range of diagnostic technologies appeared to undermine 427 
adherence. 428 
 429 
Health System Structure 430 
The primary healthcare centres hosting the Chiang Rai trial were free of charge (except for unregistered 431 
minorities) and commonly accessed by poorer segments of the population, provided that these facilities 432 
were neither overcrowded or out of reach [47, 73]. The Yangon study clinics provided free healthcare 433 
as well, but were located in poor sub-urban slums with widespread unregulated access to antibiotics 434 
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and unlabelled medicine sets (so-called “drug cocktails” [62, 63, 74]). In Hanoi, the participating 435 
clinics were commonly accessed by the poor and people with health insurance, but the first and cheaper 436 
step during an illness was typically self-medication [48, 69]. Our qualitative analysis suggested that 437 
such health system configurations influenced patients’ adherence to CRP-POCT-based treatment, but 438 
they also determined the population groups who were excluded from routine access to healthcare and 439 
thus from the intervention. 440 
Local health system structures shaped the range of available healthcare choices for patients and thereby 441 
influenced their adherence to CRP-POCT-based treatment. For instance, patients who incurred a time-442 
consuming and costly visit to a primary healthcare care facility often articulated an expectation to 443 
receive some form of medication to not leave the health facility empty-handed. This was particularly 444 
pronounced in Chiang Rai, where patients’ responses often reflected explicit expectations for 445 
medicines and a sense of entitlement (“I take time to go to the doctor, if they don’t give [medicines] 446 
I’d be sad;” Patient, Chiang Rai, SSI). Similar expectations were common in Hanoi (“Some patients 447 
requested for more drugs so that they would not have to come back to the clinics at next time of being 448 
sick;” Doctor, Hanoi, FGD), also because health insurance coverage appeared to stimulate medicine 449 
expectations (“I go to the clinics because my house is very close to this clinic and medicines are 450 
covered by health insurance. So I don’t go to drug store because I have to pay for medicines;” Patient, 451 
Hanoi, SSI). The interviewed patients in Yangon had generic expectations for medicine (rather than 452 
antibiotics in particular: “The unofficial unprescribed medicines are not helpful so we come in hopes 453 
that medicines from here would cure us;” Patient, Yangon, SSI), but also seemed to access informal 454 
and private sources of medicine commonly prior to the clinic/hospital visit (“Before [coming to this 455 
clinic], I would just take the mixed medicines [“drug cocktails”], I didn’t go to the clinic,” Patient, 456 
Yangon, SSI). 457 
The health system structure also entailed target group heterogeneity in terms of exclusion from routine 458 
primary healthcare access, which shaped the potential population-level impact of the intervention. For 459 
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example, a doctor in Hanoi described that, “Patients in rural areas which are far from the hospital 460 
could not come back for re-consultation, so [they] treated themselves with antibiotics at home” 461 
(Doctor, Yangon, SSI). In Chiang Rai, villagers living in mountainous areas would cite healthcare 462 
access constraints like, “If we don’t have money, we would borrow and go buy [medicines] near our 463 
house [rather than going to the hospital]” (Patient, Chiang Rai, SSI). Also seasonal constraints were 464 
mentioned, with the workload around the rice harvest meaning that “most people would come [to the 465 
health centre] after they’re done harvesting” (Nurse, Chiang Rai). Access to formal healthcare (and 466 
thus to the CRP POCT intervention) would therefore be limited especially for poor people in rural and 467 
mountainous areas and during harvest the season. 468 
In short, the structure of the formal and informal health system determined whether other healthcare 469 
providers like pharmacies, private clinics, or even local grocery stores could absorb patients’ demand 470 
for antibiotics. Yet, healthcare access constraints like poverty and remoteness led to the exclusion of 471 
parts of the relevant target groups in all three case studies. 472 
 473 
Demand-Side Factors 474 
The third and final domain of contextual factors related to the demand side of healthcare services, 475 
influencing patients’ adherence to the CRP POCT as well as exclusion from the intervention. 476 
Patient adherence was affected when patients challenged the authority and decisions of HCWs. This 477 
was especially pronounced in Chiang Rai, where nurses rather than doctors were involved in the 478 
clinical intervention (e.g. “they’re not doctors here [at the health centre], they’re nurses;” Patient, 479 
Chiang Rai, SSI; vs. “I have gone to hospital whenever I am ill. I trust in doctors,” Patient, Hanoi, 480 
FGD). In addition, in both Yangon and Chiang Rai (for which we had more comprehensive qualitative 481 
data), patients with less formal education, from lower socio-economic strata, or with ethnic minority 482 
backgrounds would appear less assertive and more compliant with HCWs’ treatment decisions, stating 483 
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for instance that, “I don’t have any knowledge, so I’d take anything. I’d take whatever they advise” 484 
(Patient, Chiang Rai, SSI). Healthcare workers echoed this observation and described these patients as 485 
being “easy to talk to” (Nurse, Chiang Rai, SSI) and that they “don’t understand about medicines, so 486 
they do accept the treatment we give” (Doctor, Yangon, SSI). Based on these examples, we hypothesise 487 
that patient adherence is higher in settings where the power distance between HCWs and patients is 488 
larger. 489 
Adherence to the CRP POCT results could be further undermined if patients’ conceptions of illness 490 
and medicine were at odds with the implicit logic of the intervention (viz. a conceptual distinction 491 
between bacterial and non-bacterial causes of illness to guide antibiotic prescription). With few 492 
exceptions, SSI and FGD respondents in Hanoi articulated a working concept of “bacteria” and 493 
“viruses” as disease-causing agents. This conception was less prevalent among our respondents in 494 
Chiang Rai and Yangon, who would often link illness to an “inflammation” of the body (Chiang Rai) 495 
or to an infection with generic “germs” (Yangon). Respondents in these two sites also had a wider 496 
range of notions of antibiotics, which would include “anti-inflammatory medicine” (Chiang Rai), 497 
“germ killers” (Chiang Rai, Yangon), or “pesticides” (Yangon), and some patients especially in 498 
Yangon did not “quite understand what germ killers [i.e. antibiotics] are for” (Patient, Yangon, SSI). 499 
As local conceptions of illness and medicine in Chiang Rai and Yangon more often contradicted the 500 
biomedical logic of the CRP POCT, the information to explain the test might have been less effective 501 
than in Hanoi. At the same time, we observed a common pattern in Chiang Rai and Yangon that 502 
patients misinterpreted and over-estimated the capabilities of the CRP POCT as a comprehensive blood 503 
test (e.g. the finger-prick test indicating, “[…] whether this disease is good or bad, or if it’s very serious 504 
or not. And we get to know what disease it is […];” Patient, Yangon, SSI). Ironically, this discrepancy 505 
appeared to increase rather than undermine patient adherence (see [47, 74] for more discussion on this 506 
point). 507 
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Local conceptions of illness and medicine also affected exclusion from the CRP POCT: Firstly, local 508 
approaches to self-treatment with antibiotics were common in all three sites, and they could potentially 509 
involve strategies as elaborate as described by a patient in Hanoi: 510 
 511 
“Sometimes I give [my daughter] ampi [ampicillin], small capsule. After replacing it by 512 
cefexim, I found [the treatment] better. Since then, I often treat her with cefixim at home, 513 
normally for 3-5 days. If she doesn’t have fever, I will treat her at home or buy medicines from 514 
[the] drug store.” (Patient, Hanoi, SSI) 515 
 516 
While self-treatment with antibiotics was shaped partly by local conceptions of illnesses and their 517 
corresponding remedies, it was also an expression of barriers to accessing healthcare: “If [the patients] 518 
are really a hill tribe member, I don’t see them participate [in the trial], I don’t think. Because it’s 519 
hard for them to come down [from the mountain], something like that. It’s hard, it’s inconvenient” 520 
(Nurse, Chiang Rai, SSI). 521 
Secondly, a mismatch emerged in Chiang Rai and Yangon between patients’ expectations for 522 
antibiotics and the focal condition of the test: neither patients nor healthcare workers would commonly 523 
demand antibiotic treatment for a fever, unless accompanied by other symptoms (see [72] for an 524 
analysis of administrative primary-care-level data from Chiang Rai): 525 
 526 
“Anti... anti-inflammatory [i.e. antibiotic]; if they have a fever only—fever or cold—I wouldn’t 527 
prescribe [an antibiotic].” (Nurse, Chiang Rai, SSI) 528 
 529 
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Q: “Right. And when you have a fever, do you normally take anti-inflammatory [i.e. 530 
antibiotic]?” 531 
R: “For just fever, no, only Para.” 532 
Q: “There has to be a sore throat.” 533 
R: “Yes, if there’s an irritation, I’d take it right away.” (Patient, Chiang Rai, SSI) 534 
 535 
“Here they don’t ask for germ killers [i.e. antibiotics]. Because people that come here don’t 536 
have much knowledge, they might not even know that what they are taking are germ killers.” 537 
(Doctor, Yangon, SSI) 538 
 539 
“I don’t take medicine [for a fever]. I usually have a sponge bath, if I have doubts [that I have 540 
fever], I take a sponge bath. I don’t usually take medicine.” (Patient, Yangon, SSI) 541 
 542 
Owing to the incongruency between fever and antibiotic demand, a doctor in Yangon reflected that, “I 543 
don’t think that it [i.e. CRP POCT] can change much the amount of antibiotics [on the clinic level] 544 
based on whether or not to give antibiotics to those 5 or 10 people [out of 200 patients/day]” (Doctor, 545 
Yangon, SSI). 546 
In summary, a smaller power distance between HCWs and patients and discrepancies between the 547 
intervention logic and the local conceptions of the target population appeared to undermine patients’ 548 
adherence to the CRP POCT results. In addition, incongruencies between local forms of antibiotic use 549 
and the disease / healthcare provider focus of the CRP POCT intervention could diminish the potential 550 
overall impact on the population level. 551 
 552 
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Discussion 553 
Summary 554 
The objective of this paper was to contribute to the understanding of how contextual factors influence 555 
the implementation and operation of medical interventions. We compared three case studies of CRP 556 
POCT trials involving qualitative research with 130 healthcare workers and patients across Yangon 557 
(Myanmar), Chiang Rai (Thailand), and Hanoi (Vietnam). The qualitative cross-case comparison 558 
demonstrated how perceived infectious disease risks, health system factors, and the demand-side 559 
context systematically influenced clinical trial outcomes (adherence of HCWs and patients to the test 560 
results, and target group exclusion from the clinical trial). From a HCW perspective, less pronounced 561 
fears of undertreating infectious diseases by withholding antibiotics, stricter prescription monitoring, 562 
and the promotion of alternatives to antibiotic treatment appeared to reinforce adherence to the CRP 563 
POCT in Chiang Rai. The opposite was the case in Yangon and Hanoi, where absent or unenforced 564 
AMR policies appeared to undermine compliance. Patient adherence to CRP-POCT-based treatment 565 
was affected positively in Yangon and Chiang Rai, where patients tended to interpret the CRP POCT 566 
as a comprehensive blood test and therefore had a higher degree of trust in the intervention. A final 567 
example was the disease focus of the trial, which did not correspond closely with expectations for 568 
antibiotic treatment among doctors and patients in Chiang Rai and Yangon. This mismatch may have 569 
entailed a relatively higher degree of exclusion of antibiotic users among the target population 570 
compared to Hanoi. 571 
 572 
Implications 573 
The documented variation in contextual factors demonstrated how similar clinical trials operated 574 
differently across countries and different parts of their target populations. The operational variations 575 
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could influence the interpretation and generalisability of trial findings. For example, a CRP POCT trial 576 
implemented without a complementary policy environment or out of sync with local expectations for 577 
antibiotic use may yield less significant findings than otherwise, which could hinder the pursuit of 578 
further research in single-site trials unless the source of the contextual impact is clear. Likewise, trial 579 
results could appear positive yet emerge as unsustainable in routine practice if healthcare workers 580 
reverted to their accustomed behaviours during the workload-intensive monsoon season. 581 
While these implications were specific to the CRP POCT trials, we could also distil more general 582 
lessons for AMR-related interventions and for other clinical trials more broadly. For AMR-related 583 
interventions, health system factors appeared to be of fundamental importance and echoed related 584 
social sciences research on malaria rapid diagnostic testing in low- and middle-income countries. The 585 
literature has highlighted such factors as the drug supply environment, healthcare workers’ prior 586 
experience with diagnostic testing, or the availability of alternative treatment options in case of 587 
negative test results [14, 75, 76]. If AMR interventions failed to appreciate the local context (e.g. the 588 
nature of the drug procurement and monitoring systems, existing informal practices of healthcare 589 
staff), then they risk duplicating other solutions, competing with existing practices, or producing 590 
unintended consequences that potentially undermine the purpose or sustainability of the intervention. 591 
The parallels between our study and the malaria literature therefore underscore that interventions to 592 
manage and reduce antibiotic prescriptions need to respond and adapt to the local health system context 593 
[77]. 594 
The same logic holds for the demand-side context of AMR-related interventions. We highlighted the 595 
role of local conceptions and how the resulting interpretations of the CRP POCT affected patient 596 
adherence with the intervention. The theme of language and the translation of scientific into popular 597 
knowledge is not new and had been raised as an issue in the field of AMR-related behaviour change 598 
communication as well [78, 79]. Language and popular conceptions of illness thereby emerged as an 599 
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important pointer for contradictions between implicit assumptions of the AMR intervention and local 600 
realities, which our comparative case study confirmed. 601 
These points may apply to other types of clinical trials, although we cannot sustain this hypothesis 602 
without further research. Nevertheless, our work did relate to fundamental contextual impact on 603 
clinical trials in diverse settings. One problem is the potential disjunction between interventions’ 604 
assumptions and local realities. This was for instance reported in the case of directly observed therapy 605 
(DOT) as the World Health Organization’s recommended strategy for tuberculosis treatment [80, 81], 606 
which faced numerous ethical and logistical challenges like insufficient healthcare resources and 607 
insensibility to the socio-economic constraints of patients [82-84]. Our case study was a further 608 
example of such tension between internationally recommended guidelines for disease management 609 
and local health systems—manifest in the often unrealistic delayed-strategy of antibiotic prescription 610 
for uncertain diagnoses [85]. 611 
Another element of common relevance for clinical trials was target group heterogeneity. Our cross-612 
case comparison illustrated how socio-economically disadvantaged parts of the relevant target 613 
population behaved systematically differently from majority groups and struggled with participation 614 
in the trial. Such situations may not be uncommon in other low- and middle-income contexts, where 615 
poverty often renders health expenditure catastrophic [86]. Our case study therefore related to 616 
methodological arguments in the clinical trials literature according to which the treatment effect of a 617 
trial may be shaped by population heterogeneity and selection biases, and average effects may not 618 
correspond to effects of the intervention on sub-populations [87-89]. We argue that the characteristics 619 
and behaviours of the target group are important demand-side factors that require complementary 620 
qualitative evidence to help design and interpret clinical trials within the local context. 621 
 622 
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Limitations 623 
The main limitations of our research related to the slightly different implementation of the clinical 624 
trials across the three countries, to the varying depth of the qualitative data across our field sites, and 625 
to the inductive thematic analysis of our case studies. Firstly, the trial implementation differed for 626 
example in terms of the involved staff. Nurses worked at the primary care units and dedicated study 627 
nurses supported the clinical trial in Chiang Rai, while doctors and dedicated study doctors participated 628 
in the trials in Yangon and Hanoi. In Chiang Rai, the study nurses fulfilled voluntarily other functions 629 
that helped ease the workload at the health centres. This unintended trial design effect (which we did 630 
not observe in the other sites) may have increased nurses’ compliance with the trial during peak times, 631 
ceteris paribus. The trial specifications therefore evidently contributed to part of the variation across 632 
our case studies. While this limited the comparability of the trials to a certain degree, it was also partly 633 
a result of necessary local adaptation, it highlighted the interactions between trial specifications and 634 
context [10], and the broadly comparable interventions enabled us to isolate contextual factors 635 
nonetheless. 636 
Secondly, our themes potentially overemphasised the cases of Chiang Rai and Yangon, where more 637 
extensive qualitative data was collected. However, all data sets involved oral accounts from a wide 638 
array of healthcare workers and patients, and all data were analysed by local native speakers with 639 
knowledge of the CRP POCT trials to provide as much depth to the interpretation as possible. Because 640 
the emerging themes applied across all three case studies, we were confident that our analysis 641 
uncovered relevant contextual factors.  642 
Thirdly, inductive thematic analysis was chosen to identify unforeseen and locally specific factors on 643 
the basis of our informants’ narrative accounts. This meant that we were unlikely to produce an 644 
exhaustive list of all contextual factors at work in the three clinical trial case studies—especially if our 645 
respondents did not allude to them directly or indirectly, or if they applied equally across Myanmar, 646 
Thailand, and Vietnam. For example, while regional and national trade policy regimes may have 647 
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influenced trial operations through the demand and supply of antibiotics [90, 91], they did not emerge 648 
as a theme in the narratives of patients and healthcare staff. Further mixed-method research is therefore 649 
necessary to establish a geographically and conceptually comprehensive knowledge base of contextual 650 
factors affecting clinical trial outcomes. 651 
 652 
Conclusion 653 
Through a qualitative cross-case comparison involving the narrative accounts of 130 respondents and 654 
nearly one million words of transcribed material, we studied the influence of contextual factors on the 655 
effectiveness of clinical trials across three Southeast Asian countries. These trials of diagnostic 656 
biomarker tests were situated against the backdrop of antimicrobial resistance as a global health 657 
priority, wherein our focus on low- and middle-income countries in Southeast Asia offered direct 658 
insights into the realities of interventions in a global AMR epicentre. We contributed thus essential 659 
knowledge in global health and in an under-researched area of clinical trials. 660 
We identified three major domains of contextual impact on clinical trials—perceived infectious disease 661 
risks, health system factors, and the demand-side context. Yet, rather than providing a definitive list 662 
of contextual factors, our study should be understood as underscoring the importance of contextual 663 
variation in determining the effectiveness of clinical trials and the meaning of their findings. Further 664 
research should investigate the range and magnitude of contextual effects on trial outcomes through 665 
meta-analyses of large sets of clinical trials, and identify contextual variables that should be included 666 
as covariates. For this to be possible, clinical trials should collect further contextual information 667 
including their disease, health system, and demand-side environment—qualitatively and 668 
quantitatively. Ultimately, this could help to develop a “toolbox” for clinical trial designers to appraise 669 
the viability of a trial in light of its local context, and to capture the most important contextual factors 670 
during trial operation in order to interpret and situate their findings. 671 
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